<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04922307</url>
  </required_header>
  <id_info>
    <org_study_id>202548</org_study_id>
    <nct_id>NCT04922307</nct_id>
  </id_info>
  <brief_title>Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer</brief_title>
  <acronym>RESTRICT</acronym>
  <official_title>Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer Trial&#xD;
      (RESTRICT).&#xD;
&#xD;
      The primary objective is to reduce the number of units of allogenic blood transfusion in&#xD;
      locally advanced kidney cancer (≥ cT2). Secondary objectives include reduction in&#xD;
      perioperative complications, assessment of recurrence free-survival and improving overall&#xD;
      survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer Trial&#xD;
      (RESTRICT) is a randomized study to investigate blood sparing using autologous normovolemic&#xD;
      hemodilution (ANH) or cell salvage at the time of nephrectomy for locally advanced kidney&#xD;
      cancer after assessing inclusion criteria patients will be randomized to undergo standard&#xD;
      blood management including the possibility of allogenic transfusion vs autologous blood&#xD;
      transfusion. There are multiple ways patients can receive allogenic or autologous blood,&#xD;
      including veno-venous bypass or cardiopulmonary bypass (typically reserved for patients with&#xD;
      a thrombus above the level of the hepatic veins or entering the heart).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 23, 2021</start_date>
  <completion_date type="Anticipated">June 15, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of units of allogenic blood transfusions</measure>
    <time_frame>Baseline to 30 days postoperatively</time_frame>
    <description>The primary goal of the study is to evaluate the impact of the blood sparing techniques on the reduction of allogenic blood transfusion in locally advanced kidney cancer. The total number of allogenic blood units used at the end of each case will be assessed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Complications</measure>
    <time_frame>Baseline to 30 days and 90 days postoperatively</time_frame>
    <description>Number of complications will be assessed by Clavien-Dindo Index&#xD;
Grade I Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions&#xD;
Grade II Pharmacological treatment with drugs other than such allowed for grade I.&#xD;
Grade III Requiring surgical, endoscopic or radiological intervention&#xD;
IIIa Not under general anesthesia&#xD;
IIIb Under general anesthesia&#xD;
Grade IV Life-threatening complication (including CNS complications)* requiring IC/ICU- management&#xD;
IVa single organ dysfunction (including dialysis)&#xD;
IVb multiorgan dysfunction&#xD;
Grade V Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade of Complications</measure>
    <time_frame>Baseline to 30 days and 90 days postoperatively</time_frame>
    <description>Grade of complications will be assessed by Clavien-Dindo Index&#xD;
Grade I Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions&#xD;
Grade II Pharmacological treatment with drugs other than such allowed for grade I.&#xD;
Grade III Requiring surgical, endoscopic or radiological intervention&#xD;
IIIa Not under general anesthesia&#xD;
IIIb Under general anesthesia&#xD;
Grade IV Life-threatening complication (including CNS complications)* requiring IC/ICU- management&#xD;
IVa single organ dysfunction (including dialysis)&#xD;
IVb multiorgan dysfunction&#xD;
Grade V Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney Cancer Recurrence</measure>
    <time_frame>Up to 3 years postoperatively</time_frame>
    <description>Assessment of recurrence of kidney cancer by radiographic imaging (CT or MRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 3 years postoperatively</time_frame>
    <description>Assessment of survival after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by Functional Assessment of Cancer Therapy-Kidney Symptom Index (FSKI-19)</measure>
    <time_frame>Pre-operative, 1 and 3 months postoperatively</time_frame>
    <description>Assessment of quality of life measures postoperatively, scores range from 0-76, with higher scores indicating worse symptoms&#xD;
Score range: 0-76 A score of &quot;0&quot; is a severely symptomatic patient and the highest possible score is an asymptomatic patient.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Kidney Cancer</condition>
  <arm_group>
    <arm_group_label>Blood Sparing Protocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention group (120 patients) will undergo radical nephrectomy with blood-sparing techniques. Acute Normovolemic Hemodilution (ANH) collects patients own blood prior to the start of surgical procedure; Cell saver is the collection of blood lost during surgery with subsequent auto-transfusion of the patients own cells; Veno-venous bypass will be used for patients with anticipated large loss of blood during surgery (&gt;1L). The patients in the interventional group will be blinded to which blood sparing techniques utilized.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Blood Replacement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group of one hundred and twenty (120) patients will undergo radical nephrectomy without blood sparing techniques (ie. Standard of care). Patients who need blood transfusion will receive cross-matched allogenic blood products.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Sparing Protocol</intervention_name>
    <description>Acute Normovolemic Hemodilution, Cell Saver, and/or Veno-venous Bypass</description>
    <arm_group_label>Blood Sparing Protocol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard Blood Replacement</intervention_name>
    <description>Allogenic blood transfusion as determined intra-operatively</description>
    <arm_group_label>Standard Blood Replacement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Renal masses ≥ cT2 (by any conventional imaging).&#xD;
&#xD;
          -  N1 or M1 disease is allowed if they are deemed surgical candidates (including&#xD;
             cytoreductive nephrectomy).&#xD;
&#xD;
          -  Male and female patients.&#xD;
&#xD;
          -  18 and older.&#xD;
&#xD;
          -  Ejection fraction (EF) ≥ 45% by echocardiogram (ECHO).&#xD;
&#xD;
          -  Adequate organ function as defined by:&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g/dL. Pre-operative allogenic blood transfusion is allowed.&#xD;
&#xD;
               -  Platelets ≥ 100.000/μl.&#xD;
&#xD;
               -  Albumin ≥ 2.5 g/dL.&#xD;
&#xD;
               -  Aspartate Aminotransferase (AST) and alanine transaminase (ALT) ≤ 75U/L or total&#xD;
                  bilirubin ≤ 2.0 mg/dL.&#xD;
&#xD;
               -  WBC within institutional normal limits.&#xD;
&#xD;
               -  PT within institutional normal limits.&#xD;
&#xD;
               -  INR &lt; 1.5 and PTT normal.&#xD;
&#xD;
               -  Consent and compliance with all aspects of the study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Male and female younger than 18 years old.&#xD;
&#xD;
          -  Non-surgical candidate&#xD;
&#xD;
          -  Unstable angina.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kelvin Moses</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kelvin Moses, MD, PhD</last_name>
    <phone>615-343-1317</phone>
    <email>kelvin.a.moses@vumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pam Steele</last_name>
    <phone>615-343-2120</phone>
    <email>pam.steele@vumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe Spiess, MD</last_name>
      <phone>813-745-8343</phone>
      <email>philippe.spiess@moffitt.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute at Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Viraj Master, MD, PhD</last_name>
      <phone>404-778-4898</phone>
      <email>vmaster@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pam Steele</last_name>
      <phone>615-343-2120</phone>
      <email>pam.steele@vumc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 4, 2021</study_first_submitted>
  <study_first_submitted_qc>June 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Kelvin Moses</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>nephrectomy</keyword>
  <keyword>blood sparing</keyword>
  <keyword>allogenic blood transfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

